Idecabtagene vicleucel for relapsed/refractory multiple myeloma: a review of recent advances.
Sign Up to like & getrecommendations! Published in 2022 at "Drugs of today"
DOI: 10.1358/dot.2022.58.3.3381592
Abstract: The introduction of new classes of drugs for the treatment of multiple myeloma (MM) in the past 2 decades, such as proteasome inhibitors, immunomodulators and anti-CD38 monoclonal antibodies, coupled with autologous stem cell transplantation, has… read more here.
Keywords: idecabtagene vicleucel; review; advances idecabtagene; vicleucel relapsed ... See more keywords